# Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

> **NCT05461456** · PHASE1 · COMPLETED · sponsor: **OrchestratePharma GmbH** · enrollment: 12 (actual)

## Conditions studied

- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Atopic Rash
- Rash
- Pruritus
- Urticaria
- Urticaria Chronic
- Psoriasis
- Psoriasis Vulgaris
- Skin Rash
- Skin Inflammation
- Eczema

## Interventions

- **DRUG:** Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)

## Key facts

- **NCT ID:** NCT05461456
- **Lead sponsor:** OrchestratePharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2022-10-16
- **Final completion:** 2022-10-16
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461456, "Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05461456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*